GSK will help CureVac manufacture up to 100 million doses of the German biotech’s first-generation mRNA COVID vaccine candidate, CVnCoV, in 2021, the two companies said Wednesday. In the meantime, the two companies will also work on a next-gen vaccine to tackle emerging variants. Source: Fierce Pharma 3/2/21